85-66-5

Usage

Uses

Used in Pharmaceutical Applications:
Pyocyanine is used as a regulator to disable the ability of forkhead box A2 (FOXA2) in controlling goblet cell hyperplasia and metaplasia (GCHM) and mucin expression.
Used in Cellular Signaling:
Pyocyanine is used as an activator of nuclear factor (erythroid-derived 2)-like 2 (NRF2) through the reactive oxygen species (ROS)-inducible epidermal growth factor receptor (EGFR)-phosphoinositide 3-kinase (PI3K) cellular signal transduction pathway and its downstream effectors.
Used in Microbiology Research:
Pyocyanine is used to stimulate Pseudomonas aeruginosa PAO1 cell line adhesion and invasion in human lung carcinoma A549 cells via reactive oxygen species (ROS) production.
Used in Antibiotic Research:
Pyocyanine is used as an antibiotic accelerator of neutrophil apoptosis, which can potentially enhance the effectiveness of certain antibiotics in treating infections.

Biochem/physiol Actions

Pyocyanin, a blue-green pigment belonging to phenazine pigments, is a redox-active phenazine. Pyocyanin is an electron receptor, which stimulates redox cycling in bacteria, liver cells, and human epithlial cell lines. Pyocyanin enhances the oxidative metabolism, which in turn increases the formation of intracellular reactive oxygen species (ROS) via reduction of NADPH. Pyocyanin also increases the release of IL-8 by airway epithelial cells both in vitro and in vivo. This involves signal transduction pathways that include oxidants, protein tyrosine kinases, and MAP kinases. IL-8 secretion by these cells is in synergy with inflammatory cytokines. Pyocyanin has been shown to accelerate neutrophil apoptosis in vitro, resulting in resolution of acute inflammation, which is beneficial for bacteria survival.

Enzyme inhibitor

This natural pigment (FW = 210.24 g/mol), which has an antifungal activity, is a secretory agent produced by Pseudomonas aeruginosa (formerly P. pyocyanea and Bacillus pyocyaneus). It is a blue solid that is soluble in chloroform and pyridine generates reactive oxygen species, such as superoxide and hydrogen peroxide. Pyocyanine is slightly soluble in cold water and the aqueous blue solution can be decolorized under alkaline conditions upon the addition of glucose or sodium hydrosulfite. Target(s): catalase; cytochrome P450 leukotriene B4 w-oxidation; and diamine oxidase.

Purification Methods

It crystallises from H2O as dark blue needles. The picrate has m 190o (dec). [Beilstein 23 H 395, 23 I 59, 23 II 234, 23/8 V 395.]

References

1) Rada and Leto (2013),?Pyocyanin effects on respiratory epithelium: relevance in Pseudomonas Aeruginosa airway infections; Trends Microbiol.,?21?73 2) Reszka?et al. (2012),?Inactivation of the potent Pseudomonas aeruginosa cytotoxin pyocyanin by airway peroxidases and nitrite; Am. J. Physiol. Lung Cell Mol. Physiol.,?302?L1044

InChI:InChI=1/C13H10N2O/c1-15-10-6-3-2-5-9(10)14-13-11(15)7-4-8-12(13)16/h2-8H,1H3

Upstream product

• 299-11-6 phenazine methosulfate 
• 4760-34-3 N-methyl-1,2-phenylenediamine 
• 87-66-1 2-hydroxyresorcinol 
• 95-54-5 1,2-diamino-benzene 
• 1493-27-2 ortho-nitrofluorobenzene 
• 62-53-3 aniline 
• 119-75-5 2-nitro-N-phenylaniline 
• 92-82-0 Phenazin 

Downstream Products

• 6033-10-9 phenazin-1-yl acetate 
• 6055-50-1 1-Benzyloxyphenazin 
• 64-18-6 formic acid 
• 528-71-2 phenazin-1-ol 

Relevant academic research and scientific papers

A Simple and Efficient Flow Preparation of Pyocyanin a Virulence Factor of Pseudomonas aeruginosa

The synthesis of the naturally occurring toxin pyocyanin has been realized in a short 4 step sequence. The key photochemical reaction and isolation of the final product have been facilitated by the use of flow chemistry techniques and immobilised reagents. Using these procedures gram quantities of pyocyanin were easily prepared in high yield and purity.

Total Syntheses of Pyocyanin, Lavanducyanin, and Marinocyanins A and B

Total syntheses of pyocyanin, lavanducyanin, and marinocyanins A and B have been accomplished. The N-substituted phenazin-1-one skeleton, a common framework of these natural products, was constructed through the oxidative condensation of pyrogallol with N-substituted benzene-1,2-diamine under an oxygen atmosphere in a single step. Regioselective bromination with N-bromosuccinimide at the C-2 position of N-alkylated phenazin-1-ones afforded brominated natural products.

PHENAZINE DERIVATIVES AS ANTIMICROBIAL AGENTS

The present invention provides novel phenazine derivatives, such as compounds of Formula (I) and (II), and pharmaceutically acceptable salts thereof. The compounds of the invention are expected to be anitmicrobial agents and may act by a microbial warfare strategy (e.g., a reactive oxygen species (ROS)-based competition strategy). The present invention also provides pharmaceutical compositions, kits, uses, and methods that involve the compounds of the invention and may be useful in preventing or treating a microbial infection (e.g., a bacterial infection) in a subject, inhibiting the growth and/or reproduction of a microorganism (e.g., a bacterium), killing a microorganism (e.g., a bacterium), inhibiting the formation and/or growth of a biofilm, or reducing or clearing a biofilm.

Phenazine antibiotic inspired discovery of potent bromophenazine antibacterial agents against Staphylococcus aureus and Staphylococcus epidermidis

Nearly all clinically used antibiotics have been (1) discovered from microorganisms (2) using phenotype screens to identify inhibitors of bacterial growth. The effectiveness of these antibiotics is attributed to their endogenous roles as bacterial warfare agents against competing microorganisms. Unfortunately, every class of clinically used antibiotic has been met with drug resistant bacteria. In fact, the emergence of resistant bacterial infections coupled to the dismal pipeline of new antibacterial agents has resulted in a global health care crisis. There is an urgent need for innovative antibacterial strategies and treatment options to effectively combat drug resistant bacterial pathogens. Here, we describe the implementation of a Pseudomonas competition strategy, using redox-active phenazines, to identify novel antibacterial leads against Staphylococcus aureus and Staphylococcus epidermidis. In this report, we describe the chemical synthesis and evaluation of a diverse 27-membered phenazine library. Using this microbial warfare inspired approach, we have identified several bromophenazines with potent antibacterial activities against S. aureus and S. epidermidis. The most potent bromophenazine analogue from this focused library demonstrated a minimum inhibitory concentration (MIC) of 0.78-1.56 μM, or 0.31-0.62 μg mL-1, against S. aureus and S. epidermidis and proved to be 32- to 64-fold more potent than the phenazine antibiotic pyocyanin in head-to-head MIC experiments. In addition to the discovery of potent antibacterial agents against S. aureus and S. epidermidis, we also report a detailed structure-activity relationship for this class of bromophenazine small molecules.